AZD7442_PROVENT GRAPHICAL ABSTRACT.pdf (172.93 kB)
Efficacy, Safety, and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Prevention of Symptomatic COVID-19: 15-Month Final Analysis of the PROVENT and STORM CHASER Trials
Version 2 2024-05-07, 09:19
Version 1 2024-05-03, 13:52
media
posted on 2024-05-03, 13:52 authored by Adis Journals on behalf of:, Myron J. Levin, Andrew Ustianowski, Stephane de Wit, Rohini Beavon, Jesse Thissen, Seth Seegobin, Kanika Dey, Karen A Near, Katie Streicher, Alexandre Kiazand, Mark T Esser
Article full text
The article associated with this page has been accepted for online publication and is in the final stages of production. The link to the full text will be made available on this page in the next few days.
The above graphical abstract represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, and copyright information, please see the full text online (see “read the peer-reviewed publication” opposite).
